FindTrial
Sign In

10% Lidocaine spray for IUD insertion in nulliparous women

10% Lidocaine spray for pain control during intrauterine device insertion in nulliparous women: A randomized, double-blinded, placebo controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20180815004
Enrollment
124
Registered
2018-05-15
Start date
2018-07-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IUD insertion intrautetine device Lidocaine spray

Interventions

10% Lidocaine spray,Normal saline
Active Comparator Drug,Placebo Comparator Drug
Lidocaine spray,Placebo

Sponsors

Faculty of Medicine Siriraj Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Woman who required for Copper T IUD insertion Age 18-45 years New IUD user Body mass index 18.5 – 30 kg/m2 Communicable with Thai language

Exclusion criteria

Exclusion criteria: Suspicion of pregnancy Puerperal sepsis/Immediate post-septic abortion Untreated abnormal uterine bleeding Uterine anomaly/abnormal pathology distorting the uterine cavity Current pelvic inflammatory disease Untreated cervicitis/vaginitis Wilson’s disease Copper allergy known hypersensitivity to local anaesthetics. Analgesic or anxiolytic use within the last 24 h before the procedure

Design outcomes

Primary

MeasureTime frame
Pain score immediately after removal of IUD insertion tube visual analog scale—

Secondary

MeasureTime frame
side effect (uterine perforation,irritation, dizziness) after completion of IUD insertion procedure Yes of No—

Countries

Thailand

Contacts

Public ContactNalinee Panichyawat

Faculty of Medicine Siriraj Hospital

Nalinee.pan@mahidol.ac.th0896695321

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026